DURHAM, N.C.--(BUSINESS WIRE)--Bioventus, a global leader in orthobiologics, today has launched a new version of EXOGEN.com, the product website for its EXOGEN Ultrasound Bone Healing System. EXOGEN uses safe, effective low-intensity pulsed ultrasound (LIPUS) to help stimulate the body’s natural bone healing process. EXOGEN.com has a new look and feel which is designed to be more appealing to both patients and clinicians.
“EXOGEN.com has a number of features added to improve the experience of clinicians that visit the site and to facilitate a more meaningful patient experience,” said Dave Varner, Vice President, Global Marketing, Bioventus. “Specifically, patients will find a new bone healing discussion guide and patient success stories.”
Patients visiting EXOGEN.com can also access a complete portfolio of support materials that empower them to learn and connect with their therapy. An extension of this connection is provided by the EXOGEN Connects app, available to all patients to support compliance with the therapy by enabling synchronization with personal calendars.
“Clinicians can expect an improved experience at EXOGEN.com which includes expanded information and understanding of clinical conditions that benefit from use of EXOGEN by viewing our recent case studies on the metatarsal, tibia, and femur,” added Varner. “We also have links to top peer reviewed journal articles providing in-depth review of clinical efficacy and patient outcomes.”
Because of varying indications and languages, EXOGEN.com has always had country specific pages and the initial launch of the updated website includes the US, the UK/Ireland as well as Canada (English and French). The updated EXOGEN sites for Australia/New Zealand, Germany, Poland, the Netherlands, Norway, Sweden and Finland, will go live later in Q1 2018.
About Bioventus
Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Orthobiologic products from Bioventus include offerings for bone healing, bone graft and knee osteoarthritis. Its EXOGEN Ultrasound Bone Healing System uses safe, effective low intensity pulsed ultrasound (LIPUS) to stimulate the body’s natural healing process. EXOGEN has been used to treat more than 1 million patients worldwide and numerous regulatory agencies including the FDA, Health Canada, BSI, TGA, Medsafe, UAE Ministry of Health and SFDA have granted their approval of the product. Today it is the leading bone healing system in the market with complaints for lack of efficacy averaging less than 1%.
Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal.
Bioventus, the Bioventus logo, and EXOGEN are registered trademarks of Bioventus LLC.
EXOGEN - Summary of Indications for Use in the US
Summary of Indications for Use: The EXOGEN Ultrasound Bone Healing System is indicated for the non-invasive treatment of established non-unions* excluding skull and vertebra. In addition, EXOGEN is indicated for accelerating the time to a healed fracture for fresh, closed, posteriorly displaced distal radius fractures and fresh, closed or Grade I open tibial diaphysis fractures in skeletally mature individuals when these fractures are orthopaedically managed by closed reduction and cast immobilization. There are no known contraindications for the EXOGEN device. Safety and effectiveness has not been established for individuals lacking skeletal maturity; pregnant or nursing women; patients with cardiac pacemakers; on fractures due to bone cancer; or on patients with poor blood circulation or clotting problems. Some patients may be sensitive to the ultrasound gel. Full prescribing information can be found in product labeling, at www.exogen.com or by contacting customer service at 1-800-836-4080. *A nonunion is considered to be established when the fracture site shows no visibly progressive signs of healing.
